Financials

	2021	2022
Net sales	-	-
Net income	-3.66Cr -2.65Cr -2.27Cr -2.12Cr -1.94Cr -253.29Cr -3.7Cr -25Cr -9.76Cr -127.19Cr -9.93Cr -9.72Cr -420.82Cr	-3.8Cr -2.75Cr -2.35Cr -2.2Cr -2.01Cr -263Cr -3.84Cr -26Cr -10Cr -132.06Cr -10Cr -10Cr -436.94Cr
Net Debt	-1.9Cr -1.37Cr -1.17Cr -1.1Cr -1Cr -131.27Cr -1.92Cr -13Cr -5.06Cr -66Cr -5.15Cr -5.04Cr -218.09Cr	76.74L 55.48L 47.55L 44.48L 40.67L 53Cr 77.56L 5.26Cr 2.05Cr 27Cr 2.08Cr 2.04Cr 88Cr

Company Profile

IMV Inc. is a Canada-based company. The Company has sold all of its assets. It is not engaged in any business operations.

Employees

Sector

Real-time OTC Markets 01:00:04 06/06/2025 am IST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		+525.00%	+9,900.00%

24/24/24	OPEC excited about Namibia partnership, offers support	RE
16/23/16	IMV Inc., Q4 2022 Earnings Call, Mar 16, 2023

24/24/24	OPEC excited about Namibia partnership, offers support	RE
16/23/16	IMV Inc., Q4 2022 Earnings Call, Mar 16, 2023
11/22/11	IMV Inc., Q3 2022 Earnings Call, Nov 11, 2022
11/22/11	IMV Inc., Q2 2022 Earnings Call, Aug 11, 2022
29/22/29	IMV Inc. - Shareholder/Analyst Call

04/23/04	IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets	AQ
14/19/14	IMV Inc. : to Present at Two Upcoming Investor Conferences	BU
12/19/12	Imv : New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL	BU

Manager	Title	Age	Since
Stéphane Fiset CTO	Chief Tech/Sci/R&D Officer	-	-
Tracy Sherren SEC	Corporate Secretary	60	-
Marie-Eve Charrois LAW	General Counsel	-	-

Director	Title	Age	Since
Markus Warmuth BRD	Director/Board Member	55	06/11/2018
Michael Bailey CHM	Chairman	60	01/05/2022
Michael Kalos BRD	Director/Board Member	64	11/05/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Shabnam Kazmi	Option	Director	48,259	0.4121%
06/04/23	Michael Kalos	Option	Director	52,378	0.4472%
06/04/23	Markus Warmuth	Option	Director	56,007	0.4782%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMV INC.	-.--%	+525.00%	+9,900.00%	-99.96%	235
CHURCHILL CAPITAL CORP XI	-3.19%	-17.62%	-	-	81Cr
CENTIEL AG	-7.74%	-12.61%	+273.43%	-76.16%	66Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	+0.20%	-	-	65Cr
BAIN CAPITAL GSS INVESTMENT CORP.	0.00%	+0.29%	-	-	60Cr
CHURCHILL CAPITAL CORP XII	+0.33%	-0.28%	-	-	60Cr
CANTOR EQUITY PARTNERS IV, INC.	+0.44%	+0.34%	+2.52%	-	59Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.39%	+0.69%	-	-	58Cr
CHURCHILL CAPITAL CORP XIII	+0.19%	+0.19%	-	-	51Cr
Average	-1.12%	-2.31%	+3,391.98%	-88.06%	55.41Cr
Weighted average by Cap.	-1.45%	-3.22%	+145.22%	-76.16%